Gain Therapeutics, Inc.
GANX
$2.12
-$0.05-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 18.36% | -17.62% | |||
| Gross Profit | -18.36% | 17.62% | |||
| SG&A Expenses | 21.23% | 8.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.74% | -6.67% | |||
| Operating Income | -19.74% | 6.67% | |||
| Income Before Tax | -21.45% | 5.65% | |||
| Income Tax Expenses | 161.20% | -87.24% | |||
| Earnings from Continuing Operations | -23.60% | 14.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.60% | 14.13% | |||
| EBIT | -19.74% | 6.67% | |||
| EBITDA | -19.94% | 6.78% | |||
| EPS Basic | -10.67% | 20.53% | |||
| Normalized Basic EPS | -8.81% | 12.77% | |||
| EPS Diluted | -10.67% | 20.53% | |||
| Normalized Diluted EPS | -8.81% | 12.77% | |||
| Average Basic Shares Outstanding | 11.66% | 8.06% | |||
| Average Diluted Shares Outstanding | 11.66% | 8.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||